Company Insights

KNW supplier relationships

Explore interactive graphBrowse insights index
KNW supplier relationship map

Know Labs (KNW) supplier map: who gets the company to FDA clearance and commercialization

Know Labs develops and commercializes Bio‑RFID, a non‑invasive sensing platform for blood glucose and other biomarkers. The company monetizes by advancing prototypes through design, algorithm validation, clinical trials, and FDA clearance with the ultimate intent to sell consumer and medical devices and license platform capabilities to partners. KNW’s commercial strategy is outsourcing‑heavy: design, firmware, algorithm engineering, regulatory strategy and contract manufacturing are sourced from specialist partners that accelerate de‑risking and scale. For the full supplier footprint and ongoing updates, visit https://nullexposure.com/.

What the supplier mix says about KNW’s operating model

KNW runs a partner‑centric execution model that converts R&D into regulated products through third‑party expertise. That structure creates distinct business model signals investors should track:

  • Contracting posture — outsourced and modular. KNW relies on external firms for industrial design, firmware/hardware engineering, algorithm refinement and manufacturing rather than vertically integrating those capabilities.
  • Concentration risk — a few partners are mission‑critical. A named contract manufacturer for the KnowU and UBand devices concentrates execution risk in one supplier relationship.
  • Criticality — partners are directly tied to regulatory progress. Regulatory consulting and algorithm validation are essential inputs for FDA submissions and clinical trial readiness, making these suppliers operationally critical.
  • Maturity signal — incumbents and specialists. Engagements with well‑known design and manufacturing firms indicate a shift from lab prototypes to productization and scale readiness.

These operating characteristics translate into a commercial profile where time to regulatory milestone, supplier reliability, and data/algorithm readiness determine valuation inflection points rather than near‑term revenue. For ongoing supplier intelligence and to monitor changes, see https://nullexposure.com/.

Supplier roll call: who does what for KNW

Below are every relationship surfaced in the results, with a concise, plain‑English description and source reference.

Bould Design

Bould Design is providing industrial design support on an updated Know Labs prototype, bringing consumer product design pedigree to the Bio‑RFID device form factor. According to a Notebookcheck article published March 10, 2026, Bould’s experience with products like Nest and Roku underpins KNW’s efforts to productize the sensor into a user‑facing device.

Edge Impulse

Edge Impulse is collaborating with Know Labs to accelerate algorithm refinement for Bio‑RFID, a core activity required to interpret KNW’s measurement data and support larger clinical trials. This engagement was reported by Notebookcheck on March 10, 2026, and positions Edge Impulse as the algorithm engineering partner.

Igor Institute

Igor Institute has worked with Know Labs since 2018 on mechanical, electrical and firmware engineering for Bio‑RFID sensor development and optimization, providing deep product engineering continuity. Notebookcheck documented this long‑standing relationship on March 10, 2026.

NOVUS Management Group LLC

NOVUS Management Group is supplying regulatory systems and strategy guidance to prepare Know Labs for the FDA clearance process, a function that directly shapes submission pathways and documentation. Notebookcheck reported on this engagement on March 10, 2026.

Racer Technology

Racer Technology is the contracted medical device contract manufacturer (CMO) expected to manufacture the KnowU and UBand wearable devices, concentrating KNW’s production execution in a Singapore‑based partner. Notebookcheck’s March 10, 2026 write‑up names Racer as the manufacturing partner.

Hyrcanian Asset Management, LLC

Hyrcanian Asset Management appears in the results as the manager of a Bitcoin treasury trading strategy for USBC, not KNW; the reference comes from a TradingView summary of a USBC SEC filing tied to FY2025. The TradingView piece (March 2026) documents Hyrcanian’s engagement with USBC, and this entry is unrelated to Know Labs’ supplier network.

Uphold HQ Inc.

Uphold HQ Inc. is listed in the results in connection with USBC’s October 2025 collaboration to support tokenized deposit issuance; this information originates from a TradingView report summarizing USBC’s FY2025 disclosures. This relationship is not part of KNW’s supplier relationships.

Vast Bank, N.A.

Vast Bank, N.A. is cited alongside Uphold in TradingView’s reporting about USBC’s tokenized deposit infrastructure (October 2025 / FY2025), and is not a Know Labs supplier.

How these relationships affect valuation and execution risk

The supplier roster demonstrates a clear path from prototype to regulated product but concentrates risk in a handful of execution nodes:

  • Regulatory gating: NOVUS’s role makes it explicit that FDA strategy is a current focus and a primary gating item for commercialization. Regulatory milestones will be value‑driving events.
  • Algorithm and clinical readiness: Edge Impulse’s algorithm work and Igor’s sensor engineering are central to converting measurements into validated clinical endpoints; progress here determines trial readiness and clearance timelines.
  • Manufacturing concentration: Racer Technology as the named CMO centralizes production risk — any delay or quality issue there translates directly to time‑to‑market exposure.
  • Productization signal: Engagement of Bould Design is a positive commercialization signal; industrial design investment typically follows confidence in performance targets and readiness for user testing.

Investors should track deliverables and timelines from these suppliers, as regulatory approvals and successful scale manufacturing are the two primary value inflection catalysts for KNW.

For ongoing monitoring of how these supplier relationships evolve and how they affect KNW’s path to commercialization, visit https://nullexposure.com/.

Bottom line and investment actions

Know Labs is executing a deliberate, partner‑led route to commercialize Bio‑RFID: engineering and algorithm work to validate sensing, regulatory strategy to clear the devices, and contract manufacturing to scale production. The company’s valuation will be driven by regulatory progress, algorithm validation in clinical settings, and manufacturing readiness — not by early revenue. Key risk factors are supplier concentration, regulatory dependency and the reliability of algorithmic interpretation.

If your investment decision hinges on milestone timing, prioritize tracking:

  • FDA pathway updates and any public regulatory filings,
  • algorithm validation results and clinical trial starts reported by KNW and its partners,
  • manufacturing qualification and supply chain confirmations from Racer Technology.

To review the full supplier map and sign up for alerts on changes to KNW’s vendor footprint, go to https://nullexposure.com/. For a deeper supplier‑level briefing, the site aggregates ongoing reporting and supplier signals that matter for investment due diligence.